NMDA Receptor Modulators for Neuropathic Pain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel and more specific/potent compounds that can bind to the glycine binding site of NMDA receptors, providing pharmaceutical benefits, particularly for CNS disorders such as depression, Alzheimer's disease, ADHD, schizophrenia, and anxiety, with a requirement for orally deliverable forms.
Innovation Solution
Development of compounds represented by specific chemical formulas that act as partial agonists or modulators of NMDA receptors, capable of binding to the glycine site, offering enhanced potency and therapeutic index, and formulated for oral, intravenous, or subcutaneous administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing partial agonists like GLYX-13 are used to bind to the glycine binding site of NMDA receptors, then some therapeutic effect is achieved, but potency and therapeutic index are insufficient
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical structures (changing R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 parameters) to optimize the balance between potency and therapeutic index. The chemical formulas present multiple substitutable positions that allow fine-tuning of molecular properties to achieve enhanced efficacy while maintaining safety margins.
Solution Approach 2:
The patent employs composite molecular structures combining multiple functional groups and structural elements in specific configurations. The compounds integrate various chemical moieties (aromatic rings, heterocyclic groups, substituent patterns) to create molecules with superior binding characteristics and pharmacological profiles compared to simpler existing agonists.
2Reliability
If novel compounds with enhanced potency are developed, then therapeutic efficacy is improved, but oral deliverability may be compromised
Solution Approach 1:
The patent modifies molecular parameters including molecular weight, lipophilicity, hydrogen bonding capacity, and structural rigidity to optimize oral bioavailability. The chemical structures are designed with specific substituent patterns (R1-R11) that can be adjusted to achieve the right balance between potency and pharmacokinetic properties necessary for oral administration.
Solution Approach 2:
The patent applies local quality by introducing specific functional groups and structural features at particular positions within the molecular framework. Different regions of the molecule are optimized for specific functions: some areas enhance binding affinity at the glycine site, while other regions improve solubility, stability, and absorption characteristics for oral delivery.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.